Carna Biosciences Company Description

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan.

Its products include kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions.

The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay.

In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders.

Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.

Carna Biosciences, Inc.

Country	Japan
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	63
CEO	Kohichiro Yoshino

Contact Details

Address: BMA, 1-5-5 Minatojima-Minamimachi Kobe, 650-0047 Japan
Phone	81 78 302 7039
Website	carnabio.com

Stock Details

Ticker Symbol	4572
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	JPY
ISIN Number	JP3220550002
SIC Code	2835

Key Executives

Name	Position
Kohichiro Yoshino	Chief Executive Officer
Emi Yamamoto	Chief Financial Officer